down arrow

Evolent Health, Inc.

  • Market Cap: Small Cap
  • Industry: Miscellaneous
  • ISIN: US30050B1017
USD
4.01
0.1 (2.56%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.814.02

52 Week

3.5012.98
Valuation
Technical
Day's Volume

CASH

4.58 M

Shareholding (Mar 2025)

FII

17.14%

Held by 140 FIIs

DII

21.05%

Held by 76 DIIs

Promoter

1.66%

How big is Evolent Health, Inc.?

22-Jun-2025

As of Jun 18, Evolent Health, Inc. has a market capitalization of 1,009.78 million, with net sales of 2,398.73 million and a net profit of -108.96 million over the latest four quarters.

Market Cap: As of Jun 18, Evolent Health, Inc. has a market capitalization of 1,009.78 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Evolent Health, Inc. reported net sales of 2,398.73 million and a net profit of -108.96 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,001.26 million and total assets of 2,544.41 million.

Read More

What does Evolent Health, Inc. do?

22-Jun-2025

Evolent Health, Inc. supports healthcare systems and physician organizations in transitioning to value-based care, with recent net sales of $484 million and a net loss of $65 million. The company has a market capitalization of approximately $1 billion.

Overview:<BR>Evolent Health, Inc. is engaged in healthcare delivery and payment, supporting health systems and physician organizations in transitioning to value-based care, and operates within the miscellaneous industry with a small-cap market capitalization.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 484 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -65 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,009.78 Million (Small Cap)<BR><BR>Key Metrics:<BR>Debt Equity: 0.84 <BR>Return on Equity: -8.76% <BR>Price to Book: 1.08 <BR><BR>Contact Details:<BR>Address: 800 N Glebe Rd Ste 500, ARLINGTON VA: 22203-2151 <BR>Tel: 1 571 3896000 <BR>Website: https://www.evolenthealth.com/

Read More

Who are in the management team of Evolent Health, Inc.?

22-Jun-2025

As of March 2022, Evolent Health, Inc.'s management team includes Executive Chairman and Co-Founder Frank Williams, CEO and Co-Founder Seth Blackley, and Lead Independent Director Cheryl Scott, along with Board members David Farner, Diane Holder, Kim Keck, and Independent Director Craig Barbarosh.

As of March 2022, the management team of Evolent Health, Inc. includes the following individuals:<BR><BR>- Mr. Frank Williams, who serves as the Executive Chairman of the Board and is a Co-Founder.<BR>- Mr. Seth Blackley, who is the Chief Executive Officer, a Co-Founder, and a Director.<BR>- Ms. Cheryl Scott, who is the Lead Independent Director.<BR><BR>Additionally, the Board of Directors includes Mr. David Farner, Ms. Diane Holder, Ms. Kim Keck, and Mr. Craig Barbarosh, who is an Independent Director.

Read More

Is Evolent Health, Inc. overvalued or undervalued?

20-Sep-2025

As of August 4, 2016, Evolent Health, Inc. is considered overvalued with a risky valuation grade, reflected by its high Price to Book Value of 1.06, EV to EBITDA ratio of 15.47, negative ROE of -8.76%, and significant underperformance against the S&P 500, with year-to-date and one-year returns of -22.31% and -71.66%, respectively.

As of 4 August 2016, Evolent Health, Inc. has moved from a fair to a risky valuation grade. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 1.06, an EV to EBITDA ratio of 15.47, and a ROE of -8.76%. In comparison to peers, ADT, Inc. has a P/E ratio of 10.0151 and an EV to EBITDA of 5.1174, while Shift4 Payments, Inc. shows a fair valuation with a P/E of 14.0060 and an EV to EBITDA of 12.2044, indicating that Evolent Health is trading at a premium relative to more attractively valued companies.<BR><BR>Furthermore, Evolent Health's stock has significantly underperformed against the S&P 500, with a year-to-date return of -22.31% compared to the S&P 500's 12.22%, and a staggering one-year return of -71.66% against the S&P 500's 17.14%. This stark contrast reinforces the notion that the stock is overvalued in its current state.

Read More

Is Evolent Health, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, Evolent Health, Inc. has shifted to a mildly bearish trend, indicated by bearish signals from moving averages and Bollinger Bands, despite a conflicting mildly bullish MACD on the weekly; the stock has underperformed the S&P 500 significantly, with a year-to-date return of -22.31% compared to the S&P 500's 12.22%.

As of 10 September 2025, the technical trend for Evolent Health, Inc. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by bearish signals from the daily moving averages and Bollinger Bands, along with a mildly bearish KST on the weekly timeframe. The MACD shows a conflicting mildly bullish signal on the weekly but is bearish on the monthly. The stock has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -22.31% compared to the S&P 500's 12.22%, and a one-year return of -71.66% against the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROCE of 0.44%

  • The company has been able to generate a Return on Capital Employed (avg) of 0.44% signifying low profitability per unit of total capital (equity and debt)
2

The company has declared negative results for the last 3 consecutive quarters

3

Risky - Negative Operating Profits

4

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

USD 1,151 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

1.00

stock-summary
Return on Equity

-10.28%

stock-summary
Price to Book

1.28

Revenue and Profits:
Net Sales:
444 Million
(Quarterly Results - Jun 2025)
Net Profit:
-20 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-57.74%
0%
-57.74%
6 Months
-50.55%
0%
-50.55%
1 Year
-65.16%
0%
-65.16%
2 Years
-86.33%
0%
-86.33%
3 Years
-85.97%
0%
-85.97%
4 Years
-84.76%
0%
-84.76%
5 Years
-74.05%
0%
-74.05%

Evolent Health, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Evolent Health Stock Hits Day Low of $4.92 Amid Price Pressure

Evolent Health Stock Hits Day Low of $4.92 Amid Price Pressure

Evolent Health, Inc. has faced significant volatility, hitting an intraday low and experiencing a notable decline over the past month. The company has reported negative financial results for three consecutive quarters, with substantial losses and a low return on capital employed, indicating ongoing challenges in profitability and performance.

Read More
Evolent Health Stock Plummets to New 52-Week Low at $4.92

Evolent Health Stock Plummets to New 52-Week Low at $4.92

Evolent Health, Inc. has hit a new 52-week low, trading at USD 4.92, reflecting a significant decline over the past year. The company has reported negative financial results for three consecutive quarters, with substantial losses in profit and operating cash flow, indicating ongoing financial challenges.

Read More
Evolent Health Hits New 52-Week Low at $5.97 Amidst Major Decline

Evolent Health Hits New 52-Week Low at $5.97 Amidst Major Decline

Evolent Health, Inc. has hit a new 52-week low, trading at USD 5.97, reflecting a 74.7% decline over the past year. The company has reported negative financial results for three consecutive quarters, with significant losses in profit and cash flow, raising concerns about its market position and future viability.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
18.43%
EBIT Growth (5y)
12.93%
EBIT to Interest (avg)
-0.03
Debt to EBITDA (avg)
3.44
Net Debt to Equity (avg)
0.84
Sales to Capital Employed (avg)
1.11
Tax Ratio
0.46%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0.44%
ROE (avg)
1.93%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.06
EV to EBIT
-1050.09
EV to EBITDA
15.47
EV to Capital Employed
1.03
EV to Sales
0.74
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-0.10%
ROE (Latest)
-8.76%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Bearish
Bearish
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 88 Schemes (60.15%)

Foreign Institutions

Held by 140 Foreign Institutions (17.14%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -31.34% vs 37.95% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -1,343.75% vs 104.66% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "444.30",
          "val2": "647.10",
          "chgp": "-31.34%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "27.30",
          "val2": "40.40",
          "chgp": "-32.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "11.60",
          "val2": "6.00",
          "chgp": "93.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-13.00",
          "val2": "-1.70",
          "chgp": "-664.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-19.90",
          "val2": "1.60",
          "chgp": "-1,343.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "6.40%",
          "val2": "14.60%",
          "chgp": "-0.82%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 30.08% vs 45.26% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 45.49% vs -504.28% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,554.70",
          "val2": "1,963.90",
          "chgp": "30.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "125.50",
          "val2": "154.20",
          "chgp": "-18.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "24.70",
          "val2": "54.20",
          "chgp": "-54.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-43.00",
          "val2": "-176.90",
          "chgp": "75.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-61.60",
          "val2": "-113.00",
          "chgp": "45.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.90%",
          "val2": "15.70%",
          "chgp": "-1.48%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
444.30
647.10
-31.34%
Operating Profit (PBDIT) excl Other Income
27.30
40.40
-32.43%
Interest
11.60
6.00
93.33%
Exceptional Items
-13.00
-1.70
-664.71%
Consolidate Net Profit
-19.90
1.60
-1,343.75%
Operating Profit Margin (Excl OI)
6.40%
14.60%
-0.82%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is -31.34% vs 37.95% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -1,343.75% vs 104.66% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
2,554.70
1,963.90
30.08%
Operating Profit (PBDIT) excl Other Income
125.50
154.20
-18.61%
Interest
24.70
54.20
-54.43%
Exceptional Items
-43.00
-176.90
75.69%
Consolidate Net Profit
-61.60
-113.00
45.49%
Operating Profit Margin (Excl OI)
0.90%
15.70%
-1.48%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 30.08% vs 45.26% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 45.49% vs -504.28% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Evolent Health, Inc. stock-summary
stock-summary
Evolent Health, Inc.
Miscellaneous
Evolent Health, Inc. is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company's platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models. The Company's services include providing its customers, with a population management platform, integrated data and analytics capabilities, pharmacy benefit management (PBM) services and comprehensive health plan administration services. Its value-based operations are empowered and supported by Identifi. Identifi is the Company's technology platform that aggregates and analyzes data, manages care workflows and engages patients.
Company Coordinates stock-summary
Company Details
800 N Glebe Rd Ste 500 , ARLINGTON VA : 22203-2151
stock-summary
Tel: 1 571 3896000
stock-summary
https://www.evolenthealth.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."